{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:49:33Z","timestamp":1780519773062,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital' s Funds for Health Improvement and Research","award":["CFH 2024-2-8022"],"award-info":[{"award-number":["CFH 2024-2-8022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the differences in efficacy and safety between two therapeutic approaches: glucocorticoids monotherapy and combined therapy of glucocorticoids and immunosuppressants, in patients with retroperitoneal fibrosis (RPF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic searches of PubMed, EMBASE, Cochrane Library, Web of Science and ProQuest were performed. Randomized controlled trials, quasi-experimental designs and observational cohort studies that reported the efficacy or recurrence on RPF patients treated with glucocorticoid monotherapy or glucocorticoids combined with specified immunosuppressants therapy were included. Subsequently, a meta-analysis was conducted, followed by an independent bioinformatics analysis to elucidate the mechanisms by which glucocorticoids combined with immunosuppressants potentiate therapeutic effects in the treatment of RPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 11 studies comprising 224 patients were identified. Compared with glucocorticoid monotherapy, combined therapy demonstrated a significant higher response rate (98.9% vs. 85.1%,\n                      <jats:italic>P\u2009<\/jats:italic>\n                      =\u20090.08) and a trend toward more frequent disappearance of hydronephrosis (97.1% vs. 90.0%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.29). Moreover, while recurrence rates were comparable between the two groups within the first year (5.7% vs. 4.9%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.92), recurrence in the monotherapy group surpassed that in the combined therapy group beyond 1\u00a0year of continuous follow-up (10.6% vs. 7.4% at 24\u00a0months, 21.1% vs. 10.7% at 36\u00a0months, and 26.1% vs. 12.5% overall), although without significant difference. Bioinformatic analysis revealed that prednisone targets overlapping with RPF-associated genes are mainly involved in acute inflammatory responses and cytokine regulation, whereas immunosuppressants act on a broader range of pathogenic genes implicated in key immunological and fibrotic pathways in RPF. This complementary targeting provides a mechanistic rationale for the role of immunosuppressants in promoting fibrotic tissue remodeling and alleviating mechanical obstruction in RPF. The use of immunosuppressants was associated with a low incidence of adverse events (7.2%), and no severe side effects were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical evidence from literature and mechanistic insights from bioinformatics both suggest a potential benefit of combination therapy in RPF. However, the evidence remains associative and exploratory. Further randomized controlled trials are warranted to evaluate the potential benefits and risks associated with the addition of immunosuppressants in patients with RPF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-026-03856-5","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T01:35:57Z","timestamp":1772933757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glucocorticoid monotherapy vs. immunosuppressant-combined therapy in retroperitoneal fibrosis: clinical evidence and mechanistic insights from bioinformatics"],"prefix":"10.1186","volume":"31","author":[{"given":"Tong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8152-2489","authenticated-orcid":false,"given":"Cuiping","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9603-6128","authenticated-orcid":false,"given":"Yuexian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-9767","authenticated-orcid":false,"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"1","key":"3856_CR1","first-page":"60","volume":"73","author":"J G\u00f3mez Rivas","year":"2020","unstructured":"G\u00f3mez Rivas J, Quintana LM, \u00c1lvarez-Maestro M, et al. Retroperitoneal fibrosis: a literature review. Arch Esp Urol. 2020;73(1):60\u20137.","journal-title":"Arch Esp Urol"},{"issue":"9506","key":"3856_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","volume":"367","author":"A Vaglio","year":"2006","unstructured":"Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006;367(9506):241\u201351.","journal-title":"Lancet"},{"issue":"7","key":"3856_CR3","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2015101110","volume":"27","author":"A Vaglio","year":"2016","unstructured":"Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol. 2016;27(7):1880\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"3856_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073980","volume":"383","author":"EF Morand","year":"2023","unstructured":"Morand EF, Fernandez-Ruiz R, Blazer A, et al. Advances in the management of systemic lupus erythematosus. BMJ. 2023;383:e073980.","journal-title":"BMJ"},{"issue":"1","key":"3856_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S, et al. EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3856_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"D1","key":"3856_CR7","doi-asserted-by":"publisher","first-page":"D877","DOI":"10.1093\/nar\/gkw1012","volume":"45","author":"N Rappaport","year":"2017","unstructured":"Rappaport N, Twik M, Plaschkes I, et al. MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Res. 2017;45(D1):D877\u201387.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3856_CR8","first-page":"D845","volume":"48","author":"J Pi\u00f1ero","year":"2020","unstructured":"Pi\u00f1ero J, Ram\u00edrez-Anguita JM, Sa\u00fcch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845\u201355.","journal-title":"Nucleic Acids Res"},{"key":"3856_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/cpbi.5","author":"G Stelzer","year":"2016","unstructured":"Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards Suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016. https:\/\/doi.org\/10.1002\/cpbi.5.","journal-title":"Curr Protoc Bioinformatics"},{"issue":"W1","key":"3856_CR10","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357\u201364.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3856_CR11","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, et al. DrugBank 6.0: the DrugBank knowledgebase for 2024. Nucleic Acids Res. 2024;52(D1):D1265\u201375.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3856_CR12","doi-asserted-by":"publisher","first-page":"D930","DOI":"10.1093\/nar\/gky1075","volume":"47","author":"D Mendez","year":"2019","unstructured":"Mendez D, Gaulton A, Bento AP, et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 2019;47(D1):D930\u201340.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3856_CR13","doi-asserted-by":"publisher","first-page":"D1328","DOI":"10.1093\/nar\/gkae883","volume":"53","author":"AP Davis","year":"2025","unstructured":"Davis AP, Wiegers TC, Sciaky D, et al. Comparative toxicogenomics database\u2019s 20th anniversary: update 2025. Nucleic Acids Res. 2025;53(D1):D1328\u201334.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"3856_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nbt1284","volume":"25","author":"MJ Keiser","year":"2007","unstructured":"Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25(2):197\u2013206.","journal-title":"Nat Biotechnol"},{"issue":"D1","key":"3856_CR15","doi-asserted-by":"publisher","first-page":"D1465","DOI":"10.1093\/nar\/gkad751","volume":"52","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhang Y, Zhao D, et al. TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024;52(D1):D1465\u201377.","journal-title":"Nucleic Acids Res"},{"key":"3856_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1084","author":"SL Freshour","year":"2021","unstructured":"Freshour SL, Kiwala S, Cotto KC, et al. Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 2021. https:\/\/doi.org\/10.1093\/nar\/gkaa1084.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3856_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563\u201372.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3856_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/ar4671","volume":"16","author":"I Mizushima","year":"2014","unstructured":"Mizushima I, Inoue D, Yamamoto M, et al. Clinical course after corticosteroid therapy in IgG4-related aortitis\/periaortitis and periarteritis: a retrospective multicenter study. Arthritis Res Ther. 2014;16(4):R156.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3856_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14712\/23362936.2016.3","volume":"117","author":"M Prucha","year":"2016","unstructured":"Prucha M, Kolombo I, Stadler P. Combination of steroids and azathioprine in the treatment of Ormond\u2019s disease--a single centre retrospective analysis. Prague Med Rep. 2016;117(1):34\u201341.","journal-title":"Prague Med Rep"},{"issue":"1","key":"3856_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.juro.2007.03.057","volume":"178","author":"PJ Scheel Jr","year":"2007","unstructured":"Scheel PJ Jr, Piccini J, Rahman MH, et al. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol. 2007;178(1):140\u20134.","journal-title":"J Urol"},{"issue":"9","key":"3856_CR21","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/ndt\/gfl228","volume":"21","author":"G Moroni","year":"2006","unstructured":"Moroni G, Gallelli B, Banfi G, et al. Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and\/or medical approaches. Nephrol Dial Transplant. 2006;21(9):2485\u201390.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"3856_CR22","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1136\/annrheumdis-2013-203267","volume":"72","author":"F Alberici","year":"2013","unstructured":"Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis. 2013;72(9):1584\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3856_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/ckj\/sfv148","volume":"9","author":"FE van der Bilt","year":"2016","unstructured":"van der Bilt FE, Hendriksz TR, van der Meijden WA, et al. Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy. Clin Kidney J. 2016;9(2):184\u201391.","journal-title":"Clin Kidney J"},{"issue":"9788","key":"3856_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(11)60934-3","volume":"378","author":"A Vaglio","year":"2011","unstructured":"Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet. 2011;378(9788):338\u201346.","journal-title":"Lancet"},{"key":"3856_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.mehy.2018.11.005","volume":"122","author":"A Soriano Rios","year":"2019","unstructured":"Soriano Rios A, Paredes H, Hern\u00e1ndez-Calleros J, et al. Retroperitoneal fibrosis. Steroid treatment response seems to depend on its association to IgG4 related disease. Med Hypotheses. 2019;122:120\u20133.","journal-title":"Med Hypotheses"},{"issue":"10","key":"3856_CR26","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/rheumatology\/ken291","volume":"47","author":"S Adler","year":"2008","unstructured":"Adler S, Lodermeyer S, Gaa J, et al. Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology. 2008;47(10):1535\u20138.","journal-title":"Rheumatology"},{"issue":"10","key":"3856_CR27","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2298\/VSP170714008O","volume":"76","author":"K Obrencevic","year":"2019","unstructured":"Obrencevic K, Petroviv D, Aleksic P, et al. Successful treatment of idiopathic retroperitoneal fibrosis with combined immunosuppressive therapy. Vojnosanit Pregl. 2019;76(10):1014\u201321.","journal-title":"Vojnosanit Pregl"},{"issue":"7","key":"3856_CR28","first-page":"1544","volume":"41","author":"F Vianello","year":"2023","unstructured":"Vianello F, Romano Gargarella L, Cinetto F, et al. Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol. 2023;41(7):1544\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"3856_CR29","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/ndt\/gfaa083","volume":"36","author":"V Raglianti","year":"2021","unstructured":"Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant. 2021;36(10):1773\u201381.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3856_CR30","doi-asserted-by":"publisher","first-page":"9859","DOI":"10.1038\/s41467-024-52586-x","volume":"15","author":"HJ Faust","year":"2024","unstructured":"Faust HJ, Cheng TY, Korsunsky I, et al. Adipocyte associated glucocorticoid signaling regulates normal fibroblast function which is lost in inflammatory arthritis. Nat Commun. 2024;15(1):9859.","journal-title":"Nat Commun"},{"key":"3856_CR31","unstructured":"Chourpiliadis C, Aeddula NR. Physiology, Glucocorticoids. StatPearls. Treasure Island (FL) with ineligible companies. Disclosure: Narothama Aeddula declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2025. StatPearls Publishing LLC. 2025."},{"key":"3856_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101809","volume":"83","author":"X Wu","year":"2023","unstructured":"Wu X, Qian L, Zhao H, et al. CXCL12\/CXCR4: an amazing challenge and opportunity in the fight against fibrosis. Ageing Res Rev. 2023;83:101809.","journal-title":"Ageing Res Rev"},{"key":"3856_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205023","author":"Y Bedoui","year":"2019","unstructured":"Bedoui Y, Guillot X, S\u00e9lambarom J, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20205023.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3856_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1600-6143.2010.03413.x","volume":"11","author":"X He","year":"2011","unstructured":"He X, Smeets RL, Koenen HJ, et al. Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation. Am J Transplant. 2011;11(3):439\u201349.","journal-title":"Am J Transplant"},{"issue":"1","key":"3856_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12016-023-08963-3","volume":"65","author":"R Bhat","year":"2023","unstructured":"Bhat R, Tonutti A, Timilsina S, et al. Perspectives on mycophenolate mofetil in the management of autoimmunity. Clin Rev Allergy Immunol. 2023;65(1):86\u2013100.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"3856_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.immuni.2014.06.006","volume":"41","author":"I Tindemans","year":"2014","unstructured":"Tindemans I, Serafini N, Di Santo JP, et al. GATA-3 function in innate and adaptive immunity. Immunity. 2014;41(2):191\u2013206.","journal-title":"Immunity"},{"key":"3856_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249739","author":"GA Cabral-Pacheco","year":"2020","unstructured":"Cabral-Pacheco GA, Garza-Veloz I, la Castruita-De Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21249739.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3856_CR38","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1161\/HYPERTENSIONAHA.117.09045","volume":"69","author":"A Takawale","year":"2017","unstructured":"Takawale A, Zhang P, Patel VB, et al. Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63-integrin \u03b21 interaction. Hypertension. 2017;69(6):1092\u2013103.","journal-title":"Hypertension"},{"issue":"4","key":"3856_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e42452","volume":"11","author":"G Vijayakumar","year":"2025","unstructured":"Vijayakumar G, Latha A, Anil AP, et al. Cell autonomous TLR4 signaling modulates TGF-\u03b2 induced activation of human cardiac fibroblasts. Heliyon. 2025;11(4):e42452.","journal-title":"Heliyon"},{"key":"3856_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98850","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S, Wang W, Qin W, et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.98850.","journal-title":"JCI Insight"},{"issue":"2","key":"3856_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114677","volume":"450","author":"N Li","year":"2025","unstructured":"Li N, Lu XY, Zhang JY, et al. PAI-1 regulates extracellular matrix remodeling and alters fibroblast profibrotic ability in skeletal muscle repair. Exp Cell Res. 2025;450(2):114677.","journal-title":"Exp Cell Res"},{"issue":"1","key":"3856_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38(1):13\u201325.","journal-title":"Immunity"},{"issue":"3","key":"3856_CR43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180\u201390.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3856_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12026-011-8205-2","volume":"50","author":"S Goenka","year":"2011","unstructured":"Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunol Res. 2011;50(1):87\u201396.","journal-title":"Immunol Res"},{"issue":"1","key":"3856_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64096-5","volume":"16","author":"G Wu","year":"2025","unstructured":"Wu G, Yang C, Huang Y, et al. Histone lactylation promotes rheumatoid arthritis progression by increasing NFATc2 expression and the production of anti-lactylated histone autoantibodies. Nat Commun. 2025;16(1):9034.","journal-title":"Nat Commun"},{"key":"3856_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101373","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Zhao Y, Ma X, et al. Luteolin attenuates RA-associated chronic pain by targeting the LDHA\/H3K9la\/NFATC2 axis to suppress Th17 cell differentiation and central infiltration. J Pharm Anal. 2025. https:\/\/doi.org\/10.1016\/j.jpha.2025.101373.","journal-title":"J Pharm Anal"},{"issue":"1","key":"3856_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.livres.2020.01.002","volume":"4","author":"L Chen","year":"2020","unstructured":"Chen L, Zhang Q, Yu C, et al. Functional roles of CCL5\/RANTES in liver disease. Liver Res. 2020;4(1):28\u201334.","journal-title":"Liver Res"},{"issue":"12","key":"3856_CR48","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1517\/14728222.2013.837886","volume":"17","author":"RE Marques","year":"2013","unstructured":"Marques RE, Guabiraba R, Russo RC, et al. Targeting CCL5 in inflammation. Expert Opin Ther Targets. 2013;17(12):1439\u201360.","journal-title":"Expert Opin Ther Targets"},{"key":"3856_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413348","author":"M Zaborek-\u0141yczba","year":"2021","unstructured":"Zaborek-\u0141yczba M, \u0141yczba J, Mertowska P, et al. The HLA-G immune checkpoint plays a pivotal role in the regulation of immune response in autoimmune diseases. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222413348.","journal-title":"Int J Mol Sci"},{"key":"3856_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212490","author":"N Mouchet","year":"2021","unstructured":"Mouchet N, Vu N, Turlin B, et al. Hla-G is widely expressed by mast cells in regions of organ fibrosis in the liver, lung and kidney. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222212490.","journal-title":"Int J Mol Sci"},{"key":"3856_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11091685","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wei J, Deng H, et al. The role of Nrf2 in pulmonary fibrosis: molecular mechanisms and treatment approaches. Antioxidants. 2022. https:\/\/doi.org\/10.3390\/antiox11091685.","journal-title":"Antioxidants"},{"key":"3856_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.889792","volume":"13","author":"W Hao","year":"2022","unstructured":"Hao W, Li M, Cai Q, et al. Roles of NRF2 in fibrotic diseases: from mechanisms to therapeutic approaches. Front Physiol. 2022;13:889792.","journal-title":"Front Physiol"},{"issue":"3","key":"3856_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145\u201354.","journal-title":"Nat Rev Rheumatol"},{"key":"3856_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124575","author":"S Slight-Webb","year":"2019","unstructured":"Slight-Webb S, Guthridge JM, Chakravarty EF, et al. Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.124575.","journal-title":"JCI Insight"},{"issue":"4","key":"3856_CR55","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/TP.0b013e3182247b5f","volume":"92","author":"F Abadja","year":"2011","unstructured":"Abadja F, Atemkeng S, Alamartine E, et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation. 2011;92(4):396\u2013403.","journal-title":"Transplantation"},{"issue":"7835","key":"3856_CR56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020;587(7835):555\u201366.","journal-title":"Nature"},{"issue":"6","key":"3856_CR57","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1023\/A:1021412601538","volume":"26","author":"FQ Wen","year":"2002","unstructured":"Wen FQ, Kohyama T, Sk\u00f6ld CM, et al. Glucocorticoids modulate TGF-beta production. Inflammation. 2002;26(6):279\u201390.","journal-title":"Inflammation"},{"issue":"9","key":"3856_CR58","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","volume":"20","author":"J Wang","year":"2023","unstructured":"Wang J, Zhao X, Wan YY. Intricacies of TGF-\u03b2 signaling in Treg and Th17 cell biology. Cell Mol Immunol. 2023;20(9):1002\u201322.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3856_CR59","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, et al. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21(1):104.","journal-title":"Mol Cancer"},{"issue":"6","key":"3856_CR60","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.gendis.2021.09.008","volume":"9","author":"C Hill","year":"2022","unstructured":"Hill C, Wang Y. Autophagy in pulmonary fibrosis: friend or foe? Genes Dis. 2022;9(6):1594\u2013607.","journal-title":"Genes Dis"},{"issue":"2","key":"3856_CR61","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/path.4115","volume":"229","author":"D Del Principe","year":"2013","unstructured":"Del Principe D, Lista P, Malorni W, et al. Fibroblast autophagy in fibrotic disorders. J Pathol. 2013;229(2):208\u201320.","journal-title":"J Pathol"},{"issue":"10","key":"3856_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.744","volume":"5","author":"J Wang","year":"2024","unstructured":"Wang J, Li K, Hao D, et al. Pulmonary fibrosis: pathogenesis and therapeutic strategies. MedComm. 2024;5(10):e744.","journal-title":"MedComm"},{"issue":"5","key":"3856_CR63","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/ard-2022-223736","volume":"82","author":"H Gao","year":"2023","unstructured":"Gao H, Liu S, Mai Y, et al. Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. Ann Rheum Dis. 2023;82(5):688\u201397.","journal-title":"Ann Rheum Dis"},{"key":"3856_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103487","volume":"157","author":"F Peyronel","year":"2025","unstructured":"Peyronel F, Palmisano A, Maritati F, et al. Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. J Autoimmun. 2025;157:103487.","journal-title":"J Autoimmun"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-03856-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-03856-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-03856-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:05:52Z","timestamp":1776251152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-03856-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3856"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-03856-5","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients and\/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"The manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency declaration"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"557"}}